MOIO : étude de phase III multicentrique prospective évaluant la décroissance thérapeutique de l’immunothérapie chez des patients répondeurs ayant un cancer métastatique

Liens d'intérêt

G. Gravis: Speaker bureau: Janssen, Amgen, BMS, IPSEN, AAA, AstraZeneca, Bayer, Pfizer Merck, Astellas. Recipient: my institution.

Board: Janssen, Amgen, BMS, Curium, Bayer, Pfizer Merck. Recipient: my institution. Expert: BMS, Bayer, Pfizer/Merck. Recipient: my institution. Funding: BMS Recipient UNICANCER. Travel expense: Janssen, BMS, AstraZeneca, Bayer, Pfizer Merck. Recipient: me.

F. Penault-Llorca: AbbVie, Advisory Board, Personal, DLL3 PARPi Agendia, Invited Speaker, Personal, MammaPrint and BluePrint Amgen, Advisory Board, Personal, biomarkers in lung cancer amgen, Invited Speaker, Personal, educational session biomarkers in lung cancer Astellas, Advisory Board, Personal, biomarkers in gastric cancer AstraZeneca, Advisory Board, Institutional, Strategy AstraZeneca, Advisory Board, Personal, HRD, BRCA, HER2low AstraZeneca, Invited Speaker, Personal, HRD, BRCA, HER2 low Bayer, Advisory Board, Personal, NTRK Bayer, Invited Speaker, Personal, NTRK symposium BMS, Invited Speaker, Personal, Symposium IO BMS, Advisory Board, Personal, Immunotherapy pan t Daiichi Sankyo, Advisory Board, Personal, HER2 low Daiichy Sankyo, Invited Speaker, Personal, HER2 low Eisai, Invited Speaker, Personal, Training prof breast cancer exact science, Invited Speaker, Personal, webminar on TailorX Gilead, Invited Speaker, Personal, training of Gilead employees on biomarkers in BC and symposia on Biomarkers in TNBC Gilead, Advisory Board, Personal, biomarkers in TNBC GSK, Advisory Board, Institutional, Endometrial cancer Illumina, Invited Speaker, Personal, ESMO symposium Illumina, Advisory Board, Personal, NGS Janssen, Invited Speaker, Institutional, hospitalization at home Janssen, Invited Speaker, Personal, Training prof breast cancer Lilly, Advisory Board, Personal, Ret & breast cancer Lilly, Invited Speaker, Personal, RET & breast cancer prognosis and biomarker Lilly, Advisory Board, Institutional, Strategy MSD, Invited Speaker, Personal, Immunotherapy BRCA MSD, Advisory Board, Personal, Symposium preparation Novartis, Advisory Board, Personal, PIK3CA and biomarkers in general Novartis, Invited Speaker, Personal, PIK3CA Pfizer, Advisory Board, Personal, ER+ breast cancer Pfizer, Invited Speaker, Personal, BRCA breast cancer, ER+ BC, biomarkers in lung cancer Pierre Fabre, Invited Speaker, Personal, HER2 breast cancer Pierre Fabre, Advisory Board, Personal, Neratinib Roche, Advisory Board, Personal, Ventana NTRK PD-L1 Roche, Invited Speaker, Personal, FMI test, biomarkers in lung cancer Roche, Other, Institutional, Clin trial pathology form review sanofi, Advisory Board, Personal, biomarkers in CRC Seagen, Advisory Board, Personal, HER2 breast cancer Seagen, Invited Speaker, Personal, her2 breast cancer Servier, Advisory Board, Personal, biomarkers in cholangiocarcinoma Bayer, Research Grant, Institutional, NTRK testing Daiichi sankyo, Local PI, Institutional, RetroBC HER2 low study Nanostring, Research Grant, Institutional, GEOMX breast TNBC.

J.P. Delord: BMS, Advisory Board, Institutional Merck Serono, Invited Speaker, Institutional MSD, Advisory Board, Institutional Pierre Fabre, Advisory Board, Institutional Roche, Advisory Board, Institutional Amgen, Research Grant, Institutional, No financial interest AstraZeneca, Research Grant, Institutional, No financial interest BMS, Research Grant, Institutional, No financial interest Genentech, Research Grant, Institutional, No financial interest MSD, Research Grant, Institutional, No financial interest Transgene, Research Grant, Institutional, No financial interest.

R. Sabatier: Research Grant from AstraZeneca, consulting fees from GSK, Advisory Boards from BMS, Clovis, Eisai, and Novartis.

D. Olive: is cofounder and shareholder of Imcheck Therapeutics, Emergence Therapeutics, Alderaan Biotechnology and Stealth IO.

The remaining authors have no conflicts of interest to declare.

Une partie de ces études ancillaires est soutenue par la fondation BMS.